Antitumor activity of ormustine against transplantable solid murine tumors. Part I

N. S. Saprykina; Сапрыкина Н. С.; L. M. Borisova; Борисова Л. М.; M. P. Kiseleva; Киселева М. П.; V. P. Krasnov; Краснов В. П.; G. L. Levit; Левит Г. Л.; V. V. Musiyak; Мусияк В. В.; M. A. Baryshnikova; Барышникова М. А.; V. M. Bukhman; Бухман В. М.; Z. S. Shprakh; Шпрах З. С.

doi:10.17650/1726-9784-2017-16-4-55-60

Antitumor activity of ormustine against transplantable solid murine tumors. Part I

Authors: Saprykina N.S.¹, Borisova L.M.¹, Kiseleva M.P.¹, Krasnov V.P.², Levit G.L.², Musiyak V.V.², Baryshnikova M.A.¹, Bukhman V.M.¹, Shprakh Z.S.¹
Affiliations:
1. N.N. Blokhin National Medical Research Center of Oncology
2. Postovsky Institute of Organic Synthesis
Issue: Vol 16, No 4 (2017)
Pages: 55-60
Section: ORIGINAL REPORTS
Published: 30.12.2017
URL: https://bioterapevt.abvpress.ru/jour/article/view/894
DOI: https://doi.org/10.17650/1726-9784-2017-16-4-55-60
ID: 894

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Background. Drugs of nitrosourea class are actively and successfully administered in oncology practice. However, at present, the search for new antitumor agents of this class is very urgent. Objective: to examine in vivo antitumor activity of ormustine, a new Russian drug from alkylnitrosourea class, against solid transplantable murine tumors: melanoma B16 and epidermoid Lewis lung carcinoma. Materials and methods. The assessment of antitumor activity of ormustine and a reference drug mustophoran (Les Labolatories Servier, France) was carried out in B6D2F1 mice. Ormustine was administered intravenously at a single dose of 50-135 mg/kg. Mustophoran was administered intravenously at a dose of 32 mg/kg twice (on days 2 and 9) and 3 times at a dose of 25 mg/kg (on days 2, 6 and 9). The follow-up period lasted till the death of animals. The antitumor effect of agents was assessed by the tumor growth inhibition and increase in life span of experimental mice compared to control animals. Results. It has been defined that the single intravenous dose of ormustine (125 mg/kg) is therapeutic for mice bearing melanoma B16 and epidermoid Lewis lung carcinoma. Conclusions. Ormustine possesses high antitumor effect against solid transplantable murine tumors. Ormustine is not inferior to mustophoran in the therapeutic effect against melanoma B16.

Keywords

противоопухолевые препараты, нитрозоалкилмочевина, ормустин, мюстофоран, перевиваемые опухоли мышей, antitumor agents, alkylnitrosoureas, ormustine, mustophoran, transplantable murine tumors

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Antitumor activity of ormustine against transplantable solid murine tumors. Part I

Full Text

Abstract

Keywords

About the authors

References

Supplementary files